Sunshine Biopharma (SBFM) Enterprise Value (2010 - 2026)

Sunshine Biopharma has reported Enterprise Value for 16 years, with the latest figure at -$6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 15.64% year-over-year to -$6.9 million; the trailing twelve-month figure through Mar 2026 stood at -$6.9 million (up 15.64% YoY), and the FY2025 full-year result was -$9.1 million, up 5.81% from the prior year.
• Enterprise Value for Q1 2026 stood at -$6.9 million, up from -$9.1 million in the prior quarter.
• The five-year high for Enterprise Value was -$6.9 million in Q1 2026, with the low at -$41.7 million in Q2 2022.
• Historically, Enterprise Value has averaged -$16.8 million across 5 years, with a median of -$13.2 million in 2022.
• Annual changes were most pronounced in 2022 — Enterprise Value slumped 2294.89% — and 2023, when it jumped 53.54%.
• Sunshine Biopharma's Enterprise Value stood at -$21.8 million in 2022, then gained by 25.35% to -$16.3 million in 2023, then surged by 40.55% to -$9.7 million in 2024, then climbed by 5.81% to -$9.1 million in 2025, then gained by 24.23% to -$6.9 million in 2026.
• The last three Enterprise Value figures came in at -$6.9 million (Q1 2026), -$9.1 million (Q4 2025), and -$9.3 million (Q3 2025), per Business Quant data.